In India, the launch of generic semaglutide, expected in the first quarter of FY27, is projected to boost overall Indian Pharmaceutical Market (IPM) growth by 0.5-1%. Prices are anticipated to be 30-50% lower than current levels initially, with the potential for deeper cuts of up to 70-75% o
New Delhi [India], February 12 (ANI/NewsVoir): Morepen Laboratories Ltd. is eyeing an all-new multi-billion dollar global API (Active Pharmaceutical Ingredients) market with the addition of new molecules in its bulk drugs portfolio. The focus areas of these new molecules include chronic and